Drug Profile
Adipose-derived allogeneic mesenchymal stem cell therapy - Steminent Biotherapeutics
Alternative Names: Adipose-derived allogeneic mesenchymal stem cells - Steminent; Allogeneic adipose-derived mesenchymal stem cells - Steminent Biotherapeutics; Mesenchymal stem cells - Steminent; Stemchymal®Latest Information Update: 28 Mar 2023
Price :
$50
*
At a glance
- Originator Steminent Biotherapeutics
- Developer ReproCELL; Steminent Biotherapeutics
- Class Mesenchymal stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Ataxia; Spinocerebellar ataxias
- No development reported Liver failure
Most Recent Events
- 28 Mar 2023 No recent reports of development identified for preclinical development in Ataxia in Japan (IV, Infusion)
- 28 Mar 2023 No recent reports of development identified for preclinical development in Liver-failure in Taiwan (IV, Infusion)
- 28 Oct 2022 Steminent Biotherapeutics terminates a phase-I trial in Liver failure in Taiwan considering corporate strategy (IV), , (NCT03629015)